- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02637609
Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling
Advancing Stated-preference Methods for Measuring the Preferences of Patients With Type II Diabetes
In 2012, the FDA Center for Devices and Radiological Health (CDRH) issued guidance to clarify the principal benefit-risk factors FDA considers during the reviews for premarket approval applications and de novo classification requests. In addition to a detailed description of benefits and risks, CDRH listed "patient tolerance for risk and perspective on benefit" as a factor that CDRH may consider in regulatory reviews. It underlined the need for developing methods to measure patient preference and incorporate it into regulatory decision-making. The purpose of this study is to advance methods for patient and community engagement in patient-centered outcome research (PCOR) and has three objectives.
First, demonstrate good practices for patient and community involvement in PCOR projects by applying principles of community-based participatory research (CBPR).
Second, address methodological gaps pertaining to the use of stated-preference methods in studying priorities in PCOR. These include identifying the best methods for identifying patient priorities and strategies for analyzing variation in priorities. The investigators also seek to assess the relevance of stated-preference methods to patients and stakeholders using both qualitative and quantitative methods.
Third, demonstrate good practices for applying stated-preference methods by studying the priorities of patients with type II diabetes. While type II diabetes provides an important case study, this research will advance approaches and methods that will be broadly generalizable to other diseases, and to diverse patient and stakeholder groups.
Clinical Significance:
This project will illustrate and advance methods for assessing the values of patients and stakeholders. It will demonstrate how CBPR methods apply to PCOR studies and the value of stated-preference methods in measuring the priorities of patients and stakeholders and directing health care.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participate in the GfK's KnowledgePanel
- Self-reported Type II diabetes diagnosis
Exclusion Criteria:
- Does not have Type II diabetes diagnosis
- Unable to communicate in English or Spanish
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Likert Scale
Priority elicitation survey using a Likert scale method.
|
Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
|
|
Best-Worst Scaling (Case 1)
Priority elicitation survey using a best-worst scaling method.
|
Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Priority Scores for Potential Barriers and Facilitators for Diabetes Self-management
Time Frame: One-time survey
|
Average Likert score or best-worst score that measures the impact of each factor on diabetes self-management.
Positive scores indicate facilitators for diabetes self-management while negative scores indicate barriers.
The magnitude of the score suggests the degree of the impact.
Both scales are on a +1--1 scale.
Positive 1 would be the largest possible facilitator and a negative 1 would be the largest possible barrier.
|
One-time survey
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported Difficulty in Understanding and Answering the Survey Questions
Time Frame: One-time survey
|
Questions that asked respondents to evaluate whether it was easy to understand and answer the Likert scale or BWS tasks.
|
One-time survey
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported difficulty in understanding and answering the survey questions
Time Frame: The outcome will be evaluated during the surveys conducted one year after the start of the study.
|
The survey will ask the respondents to evaluate whether it is easy to understand and answer the questions using Likert scale.
|
The outcome will be evaluated during the surveys conducted one year after the start of the study.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: John Bridges, PhD, Johns Hopkins University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCORI 90056532
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes
-
Microbio Co LtdCompleted
-
University of Malagaclinical professorNot yet recruiting
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
Baqai Institute of Diabetology and EndocrinologyNational Institute for Health Research, United Kingdom; University of York; Aga... and other collaboratorsRecruitingType II Diabetes MellitusPakistan
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Khoo Teck Puat HospitalCompletedType II Diabetes in Subjects BMI 27 to 32Singapore
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
Clinical Trials on Likert Scale
-
ElsanCimrorRecruiting
-
Ospedale Policlinico San MartinoCompletedEndometriosis, RectumItaly
-
Massachusetts General HospitalWithdrawnPatients Present With Mallet FingerUnited States
-
Mayo ClinicWithdrawn
-
Hospices Civils de LyonWithdrawnCochlear Prosthesis ImplantationFrance
-
Laboratoire Interuniversitaire de Biologie de la...CompletedHealth, Subjective | Health Behavior | Health Knowledge, Attitudes, PracticeFrance
-
Gaziosmanpasa Research and Education HospitalCompletedCovid19 | Functional CapacityTurkey
-
Biofrontera Bioscience GmbHCompleted
-
Konya Beyhekim Training and Research HospitalCompletedLow Back Pain | Cognitive DysfunctionTurkey
-
Haseki Training and Research HospitalCompletedDecision Support Systems, Clinical | Pediatrics | Clinical Decision-making | Artificial Intelligence (AI) in DiagnosisTurkey (Türkiye)